FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody capable of specifically binding to human anaphylatoxin C5a. Also disclosed is an immunosorbent for immunosorption of human anaphylatoxin C5a containing said antibody.
EFFECT: invention provides effective treatment of diseases associated with human C5a.
3 cl, 2 dwg, 2 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
CHO-SE-9/4 CELL STRAIN, PRODUCER OF CHIMERIC HUMAN ERYTHROPOIETIN ANTIBODY AND CHIMERIC ANTIBODY PRODUCED BY SAID STRAIN | 2019 |
|
RU2717038C1 |
ANTIBODIES TARGETING C5aR | 2020 |
|
RU2823245C2 |
NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR | 2016 |
|
RU2746486C2 |
Authors
Dates
2020-09-03—Published
2019-08-01—Filed